In a filing, Janux Therapeutics Inc revealed its 10% Owner Avalon Ventures XI, L.P. unloaded Company’s shares for reported $5.18 million on Sep 26 ’24. In the deal valued at $47.23 per share,109,700 shares were sold. As a result of this transaction, Avalon Ventures XI, L.P. now holds 555,727 shares worth roughly $25.25 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Avalon Ventures XI, L.P. sold 90,300 shares, generating $4,264,629 in total proceeds. Upon selling the shares at $47.23, the 10% Owner now owns 2,868,875 shares.
Before that, Avalon Ventures XI, L.P. sold 57,590 shares. Janux Therapeutics Inc shares valued at $2,675,750 were divested by the 10% Owner at a price of $46.46 per share. As a result of the transaction, Avalon Ventures XI, L.P. now holds 546,540 shares, worth roughly $24.83 million.
Stifel initiated its Janux Therapeutics Inc [JANX] rating to a Buy in a research note published on September 06, 2024; the price target was $70. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in late May with a ‘”a Sector perform”‘ rating. BTIG Research began covering JANX with “Buy” recommendation on March 21, 2024. Cantor Fitzgerald started covering the stock on March 20, 2024. It rated JANX as “an Overweight”.
Price Performance Review of JANX
On Monday, Janux Therapeutics Inc [NASDAQ:JANX] saw its stock fall -1.77% to $45.43. Over the last five days, the stock has lost -9.61%. Janux Therapeutics Inc shares have risen nearly 323.39% since the year began. Nevertheless, the stocks have risen 364.76% over the past one year. While a 52-week high of $65.60 was reached on 05/03/24, a 52-week low of $5.65 was recorded on 02/05/24. SMA at 50 days reached $43.88, while 200 days put it at $35.98.
Levels Of Support And Resistance For JANX Stock
The 24-hour chart illustrates a support level at 44.17, which if violated will result in even more drops to 42.90. On the upside, there is a resistance level at 46.86. A further resistance level may holdings at 48.28. The Relative Strength Index (RSI) on the 14-day chart is 47.31, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.98, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.58%. Stochastics %K at 38.26% indicates the stock is a holding.
How much short interest is there in Janux Therapeutics Inc?
A steep rise in short interest was recorded in Janux Therapeutics Inc stocks on 2024-09-13, growing by 54537.0 shares to a total of 3.31 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 3.25 million shares. There was a rise of 1.65%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 06, 2023 when Wedbush began covering the stock and recommended ‘”an Outperform”‘ rating along with a $24 price target.